Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLLSCellectis$2.80+0.4%$3.58$1.41▼$5.48$281.25M2.8642,412 shs40,042 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLLSCellectis-3.79%-9.42%-20.29%-12.54%+89.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLLSCellectis$2.80+0.4%$3.58$1.41▼$5.48$281.25M2.8642,412 shs40,042 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLLSCellectis-3.79%-9.42%-20.29%-12.54%+89.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLLSCellectis 2.83Moderate Buy$7.00149.82% UpsideCurrent Analyst Ratings BreakdownLatest CLLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2026CLLSCellectis BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$9.005/28/2026CLLSCellectis BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$9.004/20/2026CLLSCellectis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/14/2026CLLSCellectis Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$8.00(Data available from 6/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLLSCellectis$79.59M3.53N/AN/A$0.76 per share3.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLLSCellectis-$67.59M-$0.67N/AN/AN/A-89.51%-80.66%-20.51%7/30/2026 (Estimated)Latest CLLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026CLLSCellectis-$0.2583-$0.18+$0.0783-$0.18$11.04 million$7.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCLLSCellectisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLLSCellectis1.131.521.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLLSCellectis63.90%Insider OwnershipCompanyInsider OwnershipCLLSCellectis16.41%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLLSCellectis290100.34 million83.87 millionOptionableCLLS HeadlinesRecent News About These CompaniesCellectis S.A. (NASDAQ:CLLS) Receives Average Recommendation of "Moderate Buy" from BrokeragesJune 22 at 4:21 AM | americanbankingnews.comCellectis (NASDAQ:CLLS) Stock Price Crosses Below Fifty Day Moving Average - Time to Sell?June 16, 2026 | americanbankingnews.comCellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 CongressJune 11, 2026 | globenewswire.comCLLS stock rallies over 24% after hours — here's whyJune 9, 2026 | msn.comCellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a ...June 9, 2026 | enidnews.comECellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALLJune 9, 2026 | globenewswire.comMonthly information on share capital and company voting rightsJune 3, 2026 | globenewswire.comCellectis Calls June 25, 2026 Shareholders’ Meeting to Approve 2025 Results and Broad Capital-Issuance PowersMay 21, 2026 | tipranks.comCellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026May 20, 2026 | finance.yahoo.comCellectis' Annual Shareholders General Meeting to be Held on June 25, 2026May 20, 2026 | globenewswire.comCellectis Q1 2026 Results Highlight CAR-T Pipeline Milestones, New Epigenetic Platform and Licensing DisputeMay 14, 2026 | theglobeandmail.comCellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual CongressMay 12, 2026 | globenewswire.comCellectis Files Q1 2026 Interim Financials with U.S. SECMay 11, 2026 | tipranks.comCellectis Reports Financial Results for the First Quarter 2026May 11, 2026 | globenewswire.comMonthly information on share capital and company voting rightsMay 6, 2026 | globenewswire.comCellectis to Report First Quarter Financial Results on May 11, 2026May 4, 2026 | globenewswire.comCellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual MeetingApril 27, 2026 | globenewswire.comCema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T PlatformApril 13, 2026 | theglobeandmail.comCema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis' Allogeneic CAR-T PlatformApril 13, 2026 | globenewswire.comMonthly information on share capital and company voting rightsApril 7, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLLS Company DescriptionsCellectis NASDAQ:CLLS$2.80 +0.01 (+0.43%) As of 12:55 PM Eastern This is a fair market value price provided by Massive. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s HBM Surge Could Redefine the AI Growth Story Qualcomm’s $4B AI Deal Takes Aim at NVIDIA’s Software Moat Paychex Stock Looks Beaten Down, But Not Broken Energy Fuels Just Made a Bold Bet on Rare Earth Magnets Why KB Home Could Reward Patient Investors Later Washington’s Quantum Push Puts IBM and IonQ on the Throne FedEx’s Earnings Drop May Be Missing the Bigger Freight Story Tesla's New NHTSA Probe Lands at the Worst Possible Time Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
